|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Type of study** | **Location/setting/high or low prevalence population (based on 0.1% prevalence rate)** | **Study duration/ followup** | **Treatment groups (or comparision groups if observational study)** | **Demographics/baseline disease**  | **Eligibility criteria** | **Exclusion criteria** |
| Del Romero et al, 201093 | Prospective cohort | Madrid, Spain; HIV clinic; high prevalence (no ART: 9.2%, ART: 8.7%) | 1355 couple-years | ART vs. no ART | Index cases 83% male Female median age, 29 years Male median age, 32 years Median CD4 count, 0.500 x 109 cells/L (IQR, 0.295–0.700 x 109) Median plasma HIV RNA, 200 copies/mL (IQR, not detectable–8876) 54% detectable viral load | All heterosexual couples who had an ongoing sexual relationship over preceding 6 months, were serodiscordant for HIV, and returned for ≥1 followup visit | Nonindex partner with previous HIV diagnosis or known risk exposures other than relationship with index partner |
| Wang et al, 2010114 | Prospective cohort | County hospitals, community health centers, and home residences in Zhumadian City, Henan Province, China | Median followup: 2.84 years | Converters vs. nonconverters | Sex: 43.3% (835/1927) femaleMean age: 44.2 yearsRace/ethniticy: 99.6% Han, 0.4% Hui  | HIV-negative persons living with HIV-positive partner, in a stable marriage, and providing informed consent | None |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Number screened/eligible/ enrolled/withdrawals/% analyzed** | **Outcomes** | **Adverse events** | **Funding sourceand role** | **Quality rating** |
| Del Romero et al, 201093 | 648 eligible; 602 serodiscordant at first visit; 424 with followup | Proportion engaging in unprotected sexual intercourse, no ART vs. ART: 273/476 (57%) vs. 69/149 (46%); p=0.019Proportion of couples with previous pregnancies, no ART vs. ART: 226/476 (47%) vs. 53/149 (36%); p=0.011Transmission, no ART vs. ART: 5 instances vs. 0 instancesRate per 100 couple-years, no ART vs. ART: 0.4 (95% CI, 0.2–1.4) vs. 0 (95% CI, 0–1.1) | Not reported | Grant from FIPSE (foundation formed by Spanish Ministry of Health and Consumer Affairs and multiple pharmaceutical companies), and by Spanish Network for Research on AIDS | Fair |
| Wang et al, 2010114 | 4301 eligible; 1927 enrolled | Transmission rate: 1.71/100 person-yearsART vs. no ART: 4.8% vs. 3.2%; p=0.12Never switched ART regimen vs. switched ART regimen: RR, 2.66 (95% CI, 1.15–6.15); p=0.11 with multivariate analysis | Reasons for switching ART regimensSevere gastrointestinal symptoms: 31.8% (74/233)Skin rash: 8.6% (20/233)Anemia: 5.6% (13/233)Abnormal liver function test: 4.7% (11/233)Bone marrow suppression: 3.9% (9/233) | 11th 5-year plan of China; International Clinical Research Fellows Program at Vanderbilt | Fair |

ART = antiretroviral therapy; IQR = interquartile range.